Ra Pharma (RARX) PT Lowered to $48 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Ra Pharma (RARX) PT Raised to $49 at Raymond James After Successful Phase 2 Trial
April 10, 2019 7:30 AM EDTRaymond James analyst Steven Seedhouse raised the price target on Ra Pharma (NASDAQ: RARX) to $49.00 (from $44.00) while maintaining a Outperform rating after the company successfully completed End-of-Phase 2 interactions with the FDA and is announced it is targeting 2H19 for initiation of a pivotal Phase 3... More
Ra Pharmaceuticals (RARX) Reports Complete End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
April 9, 2019 7:01 AM EDTqa Pharmaceuticals, Inc. (NASDAQ: RARX) today announced the successful completion of End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG).
Based on feedback provided by the FDA, Ra Pharma plans to initiate a single, pivotal, Phase 3, randomized, double-blind, placebo-controlled trial evaluating the efficacy of a once-daily, subcutaneously (SC) self-administered dose of 0.3 mg/kg of zilucoplan versus placebo. The trial is expected to enroll approximately 130 patients with gMG who are acetylcholine receptor (AChR)-antibody-positive, regardless of... More
